CPC A61K 35/74 (2013.01) [A23K 10/18 (2016.05); A23L 2/52 (2013.01); A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); C07K 14/195 (2013.01); C12N 1/20 (2013.01); C12N 9/0006 (2013.01); C12N 9/0055 (2013.01); C12N 9/0057 (2013.01); C12Y 101/99 (2013.01); C12Y 110/02002 (2013.01); C12Y 110/0301 (2013.01); A23V 2002/00 (2013.01); C07K 2319/00 (2013.01); C12N 2500/14 (2013.01); C12N 2500/16 (2013.01); C12N 2500/34 (2013.01)] | 17 Claims |
1. A method of treating Alzheimer's Disease, the method comprising:
administering to a subject at risk of or suffering from Alzheimer's Disease, a therapeutically effective amount of a composition, thereby reducing the severity of at least one symptom of Alzheimer's Disease compared to a subject without the administration, and
wherein the composition comprises:
a measured amount of a bacterial species that comprises and expresses nucleic acid sequences encoding membrane-bound PQQ-dependent glucose dehydrogenase (mGDH), ubiquinol-cytochrome c reductase iron-sulfur subunit, TonB-dependent receptor, carbon-nitrogen hydrolase, and ubiquinol oxidase subunit II, or an extract or fraction derived therefrom,
wherein the extract or fraction of the bacterial species comprises membrane-bound PQQ-dependent glucose dehydrogenase (mGDH), ubiquinol-cytochrome c reductase iron-sulfur subunit, TonB-dependent receptor, carbon-nitrogen hydrolase, and ubiquinol oxidase subunit II expressed from the nucleic acid sequences,
wherein the bacterial species is from the Acetobacteriaceae family.
|